Evolent Health (EVH) Projected to Release Earnings on Thursday

Evolent Health (NYSE:EVH) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Evolent Health to announce earnings of $0.06 per share and revenue of $727.06 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The firm had revenue of $484.50 million for the quarter, compared to the consensus estimate of $597.70 million. During the same quarter last year, the firm posted ($0.10) EPS. The business’s quarterly revenue was up 46.9% compared to the same quarter last year. On average, analysts expect Evolent Health to post ($0.25) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.

Evolent Health Stock Performance

Shares of EVH stock opened at $4.41 on Tuesday. The company has a 50 day moving average price of $4.18 and a 200-day moving average price of $3.87. Evolent Health has a 52 week low of $2.10 and a 52 week high of $6.89. The firm has a market capitalization of $498.59 million, a PE ratio of -0.97 and a beta of 1.02. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 2.52.

Insider Activity

In other news, President Daniel Mccarthy sold 65,892 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total value of $329,460.00. Following the completion of the sale, the president directly owned 655,133 shares in the company, valued at $3,275,665. This represents a 9.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on EVH shares. JPMorgan Chase & Co. raised their target price on shares of Evolent Health from $5.00 to $6.00 and gave the stock an “overweight” rating in a report on Tuesday, August 18th. TD Cowen boosted their target price on shares of Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Citigroup raised Evolent Health from a “neutral” rating to a “buy” rating and lowered their price target for the company from $6.75 to $6.00 in a report on Monday, August 10th. Canaccord Genuity Group dropped their price target on Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Finally, Truist Financial cut their price objective on Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Evolent Health presently has a consensus rating of “Moderate Buy” and an average target price of $5.96.

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.